Acrivon Therapeutics
Boston, US · 3 known investors
Acrivon develops targeted precision oncology therapies matched to patients through its proteomics-based patient selection method, aiming to treat common solid cancers. Its pipeline includes clinical-stage kinase inhibitors for DNA Damage Response, cell cycle, and transcriptional regulator targets.
Founders & leadership
EG
erick gamelinin
Investors · 3
Frequently asked questions
- What does Acrivon Therapeutics do?
- Acrivon develops targeted precision oncology therapies matched to patients through its proteomics-based patient selection method, aiming to treat common solid cancers. Its pipeline includes clinical-stage kinase inhibitors for DNA Damage Response, cell cycle, and transcriptional regulator targets.
- Who are Acrivon Therapeutics's investors?
- Acrivon Therapeutics's investors include New Enterprise Associates (NEA), Pureos Bioventures, RA Capital.
- Where is Acrivon Therapeutics headquartered?
- Acrivon Therapeutics is headquartered in Boston, US.